Ticker > Company >

Zydus Lifesciences share price

Zydus Lifesciences Ltd.

NSE: ZYDUSLIFE BSE: 532321 SECTOR: Pharmaceuticals & Drugs  288k   2k   538

982.80
-12.00 (-1.21%)
BSE: 09 Dec 04:00 PM

Price Summary

Today's High

₹ 1001.95

Today's Low

₹ 981.2

52 Week High

₹ 1323.9

52 Week Low

₹ 632.05

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

98892.68 Cr.

Enterprise Value

104651.78 Cr.

No. of Shares

100.62 Cr.

P/E

22.75

P/B

5.53

Face Value

₹ 1

Div. Yield

0.31 %

Book Value (TTM)

₹  177.87

CASH

414.4 Cr.

DEBT

6173.5 Cr.

Promoter Holding

74.98 %

EPS (TTM)

₹  43.19

Sales Growth

23.9%

ROE

23.45 %

ROCE

22.95%

Profit Growth

125.05 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Zydus Lifesciences Ltd.

FALCIGO NUCOXIA OCID NUCOXIA MR LINID OXALGIN BURPEX COLIRID PAZUBID OFLIN O NUCOXIA SP TOLFREE IKMAG METSCORE XL OXALGIN MR METSCORE AM ARZEP ZYAQUA LATINA RT BRIOPT MOXTIF ILAZ ZYONATE ZYOPTA MOXTIF K AMNAC ZYVISC CYCLODROP Remdac TwinRab VaxiFlu 4 Aten DERIPHYLLIN DOXOLIN ORNI O NEUROMET DEZOCORT

Index Presence

The company is present in 37 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year23.9%
3 Year11.62%
5 Year12.37%

Profit Growth

1 Year125.05%
3 Year32.6%
5 Year18.29%

ROE%

1 Year23.45%
3 Year13.81%
5 Year13.48%

ROCE %

1 Year22.95%
3 Year14.79%
5 Year13.74%

Debt/Equity

0.3928

Price to Cash Flow

49.47

Interest Cover Ratio

11.8518

CFO/PAT (5 Yr. Avg.)

0.895927654070036

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 74.98 0.00
Jun 2024 74.98 0.00
Mar 2024 74.98 0.00
Dec 2023 74.98 0.00
Sep 2023 74.98 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 32.5971504217655% for the Past 3 years.
  • Company has a healthy Interest coverage ratio of 11.8518.
  • The Company has been maintaining an effective average operating margins of 27.2500555192279% in the last 5 years.
  • Company’s PEG ratio is 0.180023284180913.
  • The company has an efficient Cash Conversion Cycle of 45.6483 days.
  • Company has a healthy liquidity position with current ratio of 2.2227.
  • The company has a high promoter holding of 74.98%.

 Limitations

  • The company has shown a poor revenue growth of 11.617258081718% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 2159.3 2371.3 3332.4 4160.2 2620.6
Total Expenditure 1596.6 1689 1770.9 1787.3 1733
Operating Profit 562.7 682.3 1561.5 2372.9 887.6
Other Income 621.2 123.6 368.8 106.6 381.3
Interest 90.9 103.9 106.2 115.4 95.9
Depreciation 124.9 127.7 130.6 130.6 133.7
Exceptional Items 0 0 -8.6 0 0
Profit Before Tax 968.1 574.3 1684.9 2233.5 1039.3
Tax 163.1 123.9 279.7 532.7 249.5
Profit After Tax 805 450.4 1405.2 1700.8 789.8
Adjusted EPS (Rs) 7.95 4.45 13.97 16.91 7.85

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 6347.4 7780 7836.9 8731.6 10818.7
Total Expenditure 4927.5 5472.6 6065.5 6553.2 6838.1
Operating Profit 1419.9 2307.4 1771.4 2178.4 3980.6
Other Income 852.6 90.6 325.4 824.4 1162.9
Interest 233.9 70.9 134.9 278.2 390.7
Depreciation 428.9 451.1 478.7 488.6 504.4
Exceptional Items -52 -187.5 -319.3 -203.8 -8.6
Profit Before Tax 1557.7 1688.5 1163.9 2032.2 4239.8
Tax 204.1 212.3 306 503 798.3
Net Profit 1412.9 1476.2 857.9 1529.2 3441.5
Adjusted EPS (Rs.) 13.22 14.42 8.38 15.11 34.21

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 102.4 102.4 102.4 101.2 100.6
Total Reserves 11157.8 12642.1 13138.1 13538.2 15615.9
Borrowings 1511 609.5 126.4 3771 5555.4
Other N/C liabilities 1431.6 1569 1660.4 1624.3 1832.5
Current liabilities 3952.7 5163.5 4898.1 4051.2 4392
Total Liabilities 18155.5 20086.5 19925.4 23085.9 27496.4
Assets
Net Block 4109 4112 4335.9 4184.1 4369.4
Capital WIP 552.6 570.5 384 739.3 626.7
Intangible WIP 0 0 0 0 7.2
Investments 6404.1 6470.6 4897.5 4677.7 7283
Loans & Advances 1605 2398.1 2424.6 4626 5415.3
Other N/C Assets 188.7 161.1 175.8 439.5 32.9
Current Assets 5296.1 6374.2 7707.6 8419.3 9761.9
Total Assets 18155.5 20086.5 19925.4 23085.9 27496.4
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 1625.9 1688.5 1163.9 2032.2 4239.8
Adjustment 100.7 611.4 761.1 475.1 -156
Changes in Assets & Liabilities -344.8 191.1 -382.8 -1035.9 -1187
Tax Paid -201.8 -263.8 -270 -393.2 -897.7
Operating Cash Flow 1180.6 2227.2 1272.2 1078.2 1999.1
Investing Cash Flow 54.6 -2713.8 586.2 -1959.3 -1830.6
Financing Cash Flow -966.7 255.3 -1709.8 827 -300.8
Net Cash Flow 268.5 -231.3 148.6 -54.1 -132.3

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 74.98 74.98 74.98 74.98 74.98
zydus family trust (panka... 74.96 74.96 74.97 74.96 74.96
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 25.02 25.02 25.02 25.02 25.02
icici prudential bluechip... - - 1.15 - 1.40
investor education and pr... - 0.15 - 0.17 0.17
kotak flexicap fund 2.42 2.39 2.30 1.71 1.50
llife insurance corporati... 5.30 4.57 4.43 3.89 3.09
llp 0.02 0.02 0.02 0.03 0.03
icici prudential focus eq... - 1.27 - 1.26 -
investor education and pr... 0.15 - 0.15 - -

Ratings & Research Reports

Company Presentations

Company News

Zydus Lifesciences informs about details of loss of certificate 4 Dec, 2:42 PM Zydus Lifesciences - Quaterly Results 12 Nov, 12:35 PM Zydus Lifesciences - Quaterly Results 12 Nov, 12:35 PM Zydus Lifesciences - Quaterly Results 12 Nov, 12:35 PM Zydus Lifesciences informs about board meeting 30 Oct, 11:52 AM Zydus Lifesciences gets in principle acceptability from WHO for ZyVac TCV 23 Oct, 11:20 AM Zydus Lifesciences gets USFDA’s approval for Fludrocortisone Acetate Tablets 18 Oct, 9:39 AM Zydus Lifesciences gets USFDA’s final approval for Paliperidone Extended-Release Tablets 10 Oct, 2:57 PM Zydus Lifesciences gets USFDA’s tentative approval for Enzalutamide Tablets 3 Oct, 10:51 AM Zydus Lifesciences gets EIR for transdermal manufacturing facility 1 Oct, 2:07 PM Zydus Lifesciences gets nod to manufacture Enzalutamide Capsules 30 Sep, 9:50 AM Zydus Lifesciences informs about press release 27 Sep, 11:01 AM Zydus Lifesciences, CSIR- CDRI to develop drug for chronic kidney disease induced Osteoporosis 27 Sep, 11:00 AM Zydus Lifesciences informs about investor conference 18 Sep, 2:17 PM Zydus Lifesciences informs about acquisition 17 Sep, 3:52 PM Zydus Lifesciences to purchase API business of Sterling Biotech 17 Sep, 3:27 PM Zydus Lifesciences’ arm enters into licensing, supply agreement with Viwit Pharmaceuticals 13 Sep, 6:12 PM Zydus Lifesciences informs about transcript of AGM 9 Sep, 11:45 AM Zydus Lifesciences gets warning letter from USFDA for Jarod facility 30 Aug, 5:26 PM Zydus Lifesciences gets USFDA’s final approval for Scopolamine Transdermal System 30 Aug, 12:59 PM Zydus Lifesciences gets final nod to market Amantadine extended-release capsules 28 Aug, 9:23 AM Zydus Lifesciences informs about investor presentation 27 Aug, 2:52 PM Zydus Lifesciences to acquire 50% stake in Sterling Biotech from Perfect Day 24 Aug, 10:52 AM Zydus Lifesciences informs about receipt of demand order-in-original 20 Aug, 1:09 PM Zydus Lifesciences informs about press release 9 Aug, 5:54 PM Zydus Lifesciences - Quaterly Results 9 Aug, 12:55 PM Zydus Lifesciences - Quaterly Results 9 Aug, 12:55 PM Zydus Lifesciences - Quaterly Results 9 Aug, 12:55 PM Zydus Lifesciences gets USFDA’s final approval for Valbenazine Capsules 9 Aug, 12:14 PM Zydus Lifesciences informs about press release 31 Jul, 5:25 PM Zydus Lifesciences gets approval from COFEPRIS to market Mamitra 31 Jul, 12:21 PM Zydus Lifesciences informs about loss of share certificate 27 Jul, 12:14 PM Zydus Lifesciences informs about press release 23 Jul, 5:24 PM Zydus Lifesciences informs about analyst meet 23 Jul, 12:15 PM Zydus Lifesciences gets USFDA’s final approval for Valsartan Tablets 23 Jul, 12:10 PM Zydus Lifesciences gets nod to market Bhava to treat various cancers 22 Jul, 9:42 AM Zydus Lifesciences informs about press release 22 Jul, 9:32 AM Zydus Lifesciences informs about press release 19 Jul, 3:14 PM Zydus Lifesciences gets USFDA’s final approval for Zituvimet XR extended-release tablets 19 Jul, 12:30 PM USFDA classifies Zydus Lifesciences’ Jarod unit as 'official action indicated' 19 Jul, 10:29 AM Zydus Lifesciences informs about press release 18 Jul, 5:25 PM Zydus Lifesciences enters into patent licensing agreement with Takeda Pharmaceutical 18 Jul, 11:00 AM Zydus Lifesciences informs about press release 17 Jul, 5:08 PM Zydus Lifesciences gets USFDA’s tentative approval for Diroximel Fumarate Delayed-Release Capsules 10 Jul, 4:13 PM Zydus Lifesciences gets USFDA’s tentative approval for Azilsartan Medoxomil Tablets 4 Jul, 3:00 PM Zydus Lifesciences inks licensing agreement with Dr. Reddy’s Laboratories 29 Jun, 2:48 PM Zydus Lifesciences informs about details of loss of certificate 20 Jun, 12:57 PM Zydus Lifesciences informs about analyst meet 17 Jun, 12:41 PM Zydus Lifesciences gets USFDA’s tentative nod for Azilsartan Medoxomil and Chlorthalidone Tablets 14 Jun, 2:45 PM Zydus Lifesciences informs about loss of share certificate 4 Jun, 5:20 PM

Zydus Lifesciences Stock Price Analysis and Quick Research Report. Is Zydus Lifesciences an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Zydus Lifesciences and its performance over the period of time. Zydus Lifesciences stock price today is Rs 982.45.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Zydus Lifesciences cash from the operating activity was Rs 1999.1 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Zydus Lifesciences has a Debt to Equity ratio of 0.3928 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Zydus Lifesciences , the EPS growth was 126.3939 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Zydus Lifesciences has OPM of 36.7936997975727 % which is a good sign for profitability.
     
  • ROE: Zydus Lifesciences have a healthy ROE of 23.4467 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Zydus Lifesciences is Rs 982.45. One can use valuation calculators of ticker to know if Zydus Lifesciences share price is undervalued or overvalued.
Last Updated on:
Brief about Zydus Lifesciences

Zydus Lifesciences Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

Zydus Lifesciences Ltd. is a leading pharmaceutical company in India that specializes in the development, manufacturing, and marketing of a wide range of pharmaceutical products. In this article, we will provide a comprehensive analysis of Zydus Lifesciences Ltd. stock from a long-term investor's perspective. We will cover various topics such as share price, balance sheet, annual report, dividend, quarterly result, stock price, price chart, news, concall, transcripts, investor presentations, promoters, and shareholders.

Zydus Lifesciences Ltd. Share Price:

Zydus Lifesciences Ltd.'s share price is a key indicator of investor sentiment towards the company. The share price is influenced by various factors such as the company's financial performance, global economic conditions, and market sentiment. Long-term investors can use our pre-built screening tools to analyze Zydus Lifesciences Ltd.'s share price and identify any trends or patterns. The company's share price has shown a stable trend over the past few years, reflecting the company's solid financial position and growth prospects.

Zydus Lifesciences Ltd. Balance Sheet:

Zydus Lifesciences Ltd.'s balance sheet provides crucial information about its financial health. The company's assets include fixed assets, investments, and other assets, while liabilities include loans, borrowings, and other liabilities. Equity includes share capital, reserves, and surplus. Long-term investors can use our pre-built screening tools to analyze Zydus Lifesciences Ltd.'s balance sheet and identify any red flags. The company's balance sheet has shown a stable trend over the past few years, reflecting the company's solid financial position and growth prospects.

Zydus Lifesciences share capital trends  

Its share capital of Rs 102.40 crore in March 2020 has slightly come down over the period till March 2024 to Rs 100.60 crore only. This shows that there has been a relatively small number of changes in the equity structure over these years.

Zydus Lifesciences Keeps Profit Growth  

From the consolidated balance sheet at March 2020 to the balance sheet at March 2024, Zydus Lifesciences’ reserves have risen from Rs 11,157.80 crore to Rs 15,615.90 crore. This is evident of high retained earnings which acts as a backing to the projection of the financial strength of the company.

Zydus Lifesciences Debt Charges  

The creditors at first reduced it from Rs 1,511 crore in March 2020 to Rs 126.40 crore in March 2022 but rose to Rs 5,555.40 crore in March 2024. Such a rise may be attributed to new funding for development or investment in plant and equipment.

Zydus Lifesciences Asset Makeup  

Consolidated total assets of the company increased to Rs 27,496.40 crore in March 2024 from Rs 18,155.50 crore in March 2020 mainly due to increase in investment and current assets. More encouragingly, it increased from Rs 4,897.50 crore in the CR period March, 2022 to Rs 7,283 crore in the ER period of March, 2024, which underlines strategic asset investment.

Zydus Lifesciences total Current liabilities  

For current liabilities there were variations with an amount of Rs 5,163.50 crore for March 2021 and Rs 4,392 crore for March 2024. This I presume points to the work towards the efficient management of short term liabilities.

This analysis is all based on the balance sheet of Zydus Lifesciences at a standalone level. 

Regarding the pharmaceuticals sector, debt levels and reserve growth indicators could prove valuable to investors intending to screen acquisition stocks.

Zydus Lifesciences Ltd. Annual Report:

Zydus Lifesciences Ltd. releases an annual report every year, which provides detailed information about the company's financial performance, strategic initiatives, and future plans. The annual report includes a letter from the Chairman, financial statements, and management discussion and analysis. Long-term investors can download Zydus Lifesciences Ltd.'s annual report from our website and use it to make informed investment decisions. The annual report provides valuable insights into the company's operations and financial performance.

Zydus Lifesciences Ltd. Dividend:

Zydus Lifesciences Ltd. has a consistent dividend payout history. The company has paid dividends in every year, reflecting its commitment to rewarding shareholders. Long-term investors should consider this when evaluating Zydus Lifesciences Ltd.'s stock. Our pre-built screening tools can be used to analyze the company's dividend history and identify any trends or patterns.

Zydus Lifesciences Ltd. Quarterly Results:

Zydus Lifesciences Ltd. releases its quarterly results every three months. The quarterly results provide information about the company's revenue, earnings, and expenses. Long-term investors can use our pre-built screening tools to analyze Zydus Lifesciences Ltd.'s quarterly results and identify any trends or patterns. The quarterly results are an important indicator of the company's financial health and performance.

Zydus Lifesciences Ltd. Stock Price:

The stock price of Zydus Lifesciences Ltd. is affected by various factors such as the company's financial performance, global economic conditions, and market sentiment. Long-term investors can use our pre-built screening tools to track Zydus Lifesciences Ltd.'s stock price and identify potential buying opportunities. The stock price of Zydus Lifesciences Ltd. has shown a stable trend over the past few years, reflecting the company's solid financial performance and growth prospects.

Zydus Lifesciences Ltd. Price Chart:

A price chart provides a visual representation of a company's stock price over a period of time. Long-term investors can use our pre-built screening tools to analyze Zydus Lifesciences Ltd.'s price chart and identify any trends or patterns. The price chart shows that the stock price of Zydus Lifesciences Ltd. has shown a stable trend over the past few years, reflecting the company's solid financial performance and growth prospects.

Zydus Lifesciences Ltd. News:

Keeping up to date with the latest news about Zydus Lifesciences Ltd. is important for investors. Our website provides the latest news about Zydus Lifesciences Ltd. from various sources such as financial news websites and social media. Long-term investors can use this information to make informed investment decisions.

Zydus Lifesciences Ltd. Concall:

Zydus Lifesciences Ltd. holds conference calls with analysts and investors to discuss its financial performance and future plans. Long-term investors can listen to Zydus Lifesciences Ltd.'s concall and use the information provided to make informed investment decisions. Our website provides information about upcoming concalls and links to listen to past concalls.

Zydus Lifesciences Ltd. Transcripts:

Transcripts of Zydus Lifesciences Ltd.'s concalls are available on our website. Long-term investors can download the transcripts and use them to analyze the company's financial performance and future plans. The transcripts provide valuable insights into the company's operations and financial performance.

Zydus Lifesciences Ltd. Investor Presentations:

Zydus Lifesciences Ltd. provides investor presentations on its website. These presentations provide information about the company's financial performance, strategic initiatives, and future plans. Long-term investors can download Zydus Lifesciences Ltd.'s investor presentations from our website and use them to make informed investment decisions. The investor presentations provide valuable insights into the company's operations and financial performance.

Zydus Lifesciences Ltd. Promoters:

Promoters are individuals or entities that have a significant stake in a company. Zydus Lifesciences Ltd.'s promoters include the Zydus family. Long-term investors can use our pre-built screening tools to analyze Zydus Lifesciences Ltd.'s promoter holdings and identify any potential conflicts of interest. The promoter holdings of Zydus Lifesciences Ltd. are relatively stable, which is a positive sign for long-term investors.

Zydus Lifesciences Ltd. Shareholders:

Zydus Lifesciences Ltd. has a large number of shareholders, including institutional investors and individual investors. Long-term investors can use our pre-built screening tools to analyze Zydus Lifesciences Ltd.'s shareholder base and identify any potential risks or opportunities. The shareholder base of Zydus Lifesciences Ltd. is diverse, which is a positive sign for long-term investors.

Zydus Lifesciences Ltd. Premium Features:

Our website provides premium features tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. These tools can help long-term investors make better investment decisions by providing more detailed insights into the company's financial performance and valuation.

Zydus Lifesciences Limited ROCE

The Return on Capital Employed (ROCE) is an important financial ratio used to assess the profitability and efficiency of a company. For Zydus Lifesciences Limited, the ROCE ratio can be found in the financials table or ratio section of this page. ROCE measures the return generated from the capital employed in the business, including both equity and debt. By analyzing the ROCE, investors can gauge the company's ability to generate profits from its capital investments. It provides insight into the company's efficiency in utilizing its resources to generate returns for shareholders.

Zydus Lifesciences Limited EBITDA

EBITDA, an acronym for Earnings Before Interest, Taxes, Depreciation, and Amortization, is a metric commonly used to assess a company's operating performance. In the case of Zydus Lifesciences Limited, the EBITDA ratio is available in the financials table or ratio section on this page. EBITDA provides a snapshot of a company's profitability by excluding non-operating expenses and accounting considerations such as interest, taxes, and depreciation. It allows investors and analysts to evaluate the company's core operating profitability and compare it with industry peers.

Zydus Lifesciences Limited DPS

Dividends per Share (DPS) is a financial metric that represents the amount of dividend distributed to each shareholder on a per-share basis. This information is available in the financials table or ratio section on this page for Zydus Lifesciences Limited. DPS is an important indicator for investors seeking regular income from their investments. It reflects the company's willingness and ability to distribute profits to shareholders. By comparing DPS over time and across similar companies, investors can assess the stability and growth of dividend payments.

Zydus Lifesciences Limited EPS

Earnings per Share (EPS) is a fundamental financial metric that measures the profitability of a company on a per-share basis. Zydus Lifesciences Limited's EPS can be found in the financials table or ratio section on this page. EPS is commonly used by investors to evaluate a company's performance and to compare it with competitors. It indicates the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally desirable as it signifies a larger portion of earnings available to shareholders.

Read More
X